Pfizer (NY:PFE)

Pfizer stock slipped a fraction early Tuesday, but the company raised its guidance for the year and named a new CFO.

Topics Intellectual Property

Pfizer Hikes Guidance On Solid Third Quarter, Names Company Vet As New CFO ↗

November 03, 2026

Via Investor's Business Daily

Pfizer (NYSE:PFE) Beats Q3 2026 Estimates and Raises Full-Year Outlook as New Products Offset COVID Declines ↗

November 03, 2026

Via Chartmill

Pfizer (NYSE:PFE) reports strong Q3 2026, full-year outlook slightly exceeds expectations

November 03, 2026

Global pharmaceutical company Pfizer (NYSE:PFE) reported Q3 2026 results exceeding the market’s revenue expectations, but revenue was flat year on year at $1...

Pfizer Reports Strong Third-Quarter 2026 Results And Raises 2026 Guidance

November 03, 2026

From Pfizer Inc.

Pfizer Appoints Cecile Guegan as Chief Financial Officer

November 03, 2026

From Pfizer Inc.

Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits ↗

Most Active S&P 500 Stocks: Oracle, Ford, AT&T Lead Volume ↗

November 02, 2026

Via Chartmill

Topics Stocks

November 02, 2026

Panama City, Guanacaste in Costa Rica and Lagos, Portugal top one investor's list for rental income and long-term growth, with Portuguese mortgages from 2.6%.

The market for GLP-1 drugs is forecast to explode. It may be understated still.

Here's Why I Think Every Investor Needs to Invest in These "Miracle" Drugs ↗

November 02, 2026

Corporate headshot photographer NYC Michael Benabib recently recognized for his work in a one-man show in Tokyo

November 02, 2026

Via AB Newswire

1 healthcare stock with impressive fundamentals and 2 we ignore

November 01, 2026

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Shareholders who bet on the industry have been rewarded lately as...

Global pharmaceutical company Pfizer (NYSE:PFE) will be reporting results this Tuesday before market open. Here’s what to expect. Pfizer beat analysts’ reven...

Topics Economy

What to expect from Pfizer’s (PFE) Q3 earnings

November 01, 2026

Pfizer's post-COVID comeback is still only in the early stages.

Pfizer Just Hit a 52-Week High. Is the Turnaround Finally Real? ↗

October 31, 2026

Regeneron Pharmaceuticals (NASDAQ:REGN) reported third-quarter 2026 revenue growth of 36% year over year to $5.1 billion, while non-GAAP diluted earnings per share rose 70% to $20.07. The company...

Topics Intellectual Property

S&P 500 Most-Active Stocks: Oct. 30, 2026 ↗

October 30, 2026

Via Chartmill

Topics Stocks

What Regeneron Pharmaceuticals (REGN) Said on Its Q3 Earnings Call ↗

October 30, 2026

The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk tha...

Topics ETFs Earnings

1 stock under $50 worth investigating and 2 we ignore

October 29, 2026

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Luc...

Topics Energy

1 cash-producing stock with competitive advantages and 2 we brush off

October 28, 2026

The stocks listed here yield up to 5.8%.

3 Absurdly Cheap Dividend Stocks to Buy for Under $100 Right Now ↗

October 27, 2026

These three high-yield dividend stocks could surge once investors realize they've overreacted to recent headwinds.

Topics Bonds

3 Dirt Cheap Dividend Stocks to Buy Hand Over Fist ↗

October 27, 2026

Pfizer’s ELREXFIO Outperforms Standard Regimens and Meets Primary Endpoint in Phase 3 Study in Relapsed or Refractory Multiple Myeloma

Topics ETFs Intellectual Property

October 27, 2026

From Pfizer Inc.

Pfizer’s TALZENNA Plus XTANDI FDA-Approved for an Earlier Metastatic Prostate Cancer Treatment Setting

October 26, 2026

From Pfizer Inc.

EQNX::TICKER_START (NASDAQ:GTBP),(NASDAQ:MRNA),(NASDAQ:IOVA),(NASDAQ:GMAB),(NYSE:PFE) EQNX::TICKER_END

Immuno-Oncology Emerges as a Major Force in the Global Cancer Treatment Market

October 26, 2026

Via FinancialNewsMedia

Pfizer's 25-Valent Pediatric Pneumococcal Conjugate Vaccine Candidate Shows Robust Phase 2 Data at IDWeek 2026

October 24, 2026

From Pfizer Inc.

Pfizer's Dividend Yield Is One of the Highest in the S&P 500. Here's Why the Dividend Is Safer Than It Might Seem ↗

October 24, 2026

Pfizer has a plan to bounce back from recent obstacles.

Lincoln National, AbbVie and Phillips 66 offer dividends that pay investors through midterm volatility, backed by rising rates, steady drug demand and oil risk.

Topics Intellectual Property Stocks

3 Stocks With Yields Big Enough to Make Election Volatility Easier to Stomach ↗

October 23, 2026

One of these pharma stocks offers more income, but the other offers a safer dividend.

Better Dividend Stock to Buy and Hold: Pfizer or Bristol Myers Squibb? ↗

October 23, 2026

Here's how pharmaceutical stocks compare to biotech in terms of risk, rewards, and costs.

Topics Intellectual Property

Invesco Pharmaceuticals ETF vs. iShares Biotechnology ETF: Which Is the Better Buy? ↗

October 23, 2026

Prelude Therapeutics Spotlights JAK2, KAT6A Programs and Potential $100M Incyte Option ↗

Topics ETFs

October 22, 2026

Prelude Therapeutics (NASDAQ:PRLD) outlined progress across three priority programs at a Chardan Capital investor session, emphasizing its recently initiated JAK2 program, an IND-cleared KAT6A degrader...

They definitely matter... up to a point.

What Higher Interest Rates Mean for Dividend Stocks Like AbbVie and Pfizer ↗

October 22, 2026

Pfizer's revenue swung sharply lower before stabilizing, while Bristol Myers Squibb kept climbing steadily—a divergence that matters for long-term investors.

Topics Bonds Economy

Bristol Myers Squibb vs. Pfizer: Consistency vs. Scale in Revenue ↗

October 22, 2026